Henrik Andersen
About Henrik Andersen
Henrik Andersen is the Vice President and Head at Bristol-Myers Squibb in Devens, overseeing a team of approximately 350 professionals in Biologics Development.
Current Position at Bristol-Myers Squibb
Henrik Andersen serves as Vice President and Head at Bristol-Myers Squibb in Devens. Since January 2018, he has overseen approximately 350 scientists, engineers, and professionals in the Biologics Development function. His responsibilities span the development activities across multiple locations, including New Brunswick and Summit West (NJ) and Cambridge and Devens (MA). Additionally, Andersen manages clinical manufacturing operations in Summit West (NJ) and through external partners.
Previous Roles at Bristol-Myers Squibb
Before assuming his current position, Henrik Andersen held various roles at Bristol-Myers Squibb. From 2016 to 2018, he was the Executive Director and Head of Biologics MS&T Drug Substance in the Greater Boston Area. He also served as the Executive Director and Site Head at ZymoGenetics, a Bristol-Myers Squibb Company, from 2015 to 2016 in Seattle, WA. Between 2013 and 2015, Andersen was the Executive Director at ZymoGenetics, following a tenure as Senior Director from 2010 to 2013. He began his association with ZymoGenetics as a Senior Scientist in 2004 and advanced through several roles, culminating in an Executive Director position.
Educational Background
Henrik Andersen's educational journey includes a Ph.D. in Biochemistry from the University of Washington - School of Medicine, where he studied from 1996 to 2001. Prior to that, he completed his M.Sc. in Chemical Engineering at DTU - Technical University of Denmark, graduating in 1995. Andersen furthered his expertise with Executive Leadership Training at The Wharton School, which he completed in 2014.
Career Beginnings
Henrik Andersen began his career in academia, serving as an Assistant Professor at the WWAMI Program, University of Alaska Medical School, for four months in 2001-2002. He then worked as a Senior Fellow at the University of Washington for nine months in 2002 before transitioning to industry roles at ZymoGenetics Inc.